Cantourage Group SE, a leading European medical cannabis company listed on the Frankfurt Stock Exchange, has partnered with Astrasana to introduce a new range of high-THC medical cannabis flowers to the Swiss market.

The collaboration brings together Cantourage’s expertise in sourcing and quality control with Astrasana’s Swissmedic-licensed pharmaceutical distribution capabilities.

Product Range

The new flower range includes multiple cultivars with THC content optimised for therapeutic applications. All products undergo rigorous testing and quality assurance processes to meet Swiss pharmaceutical standards, including:

  • Full cannabinoid and terpene profiling
  • Microbiological testing
  • Heavy metal and pesticide screening
  • Stability studies under Swiss regulatory requirements

Market Impact

Switzerland’s medical cannabis market has seen significant growth following regulatory reforms, with increasing numbers of physicians recognising the therapeutic potential of cannabinoid-based medicines. This partnership directly addresses the growing demand for high-quality, pharmaceutical-grade cannabis flowers.

The products are available through Astrasana’s network of partner pharmacies across Switzerland, with distribution managed through their Swissmedic-licensed facility.

About Cantourage

Cantourage Group SE was founded in 2019 in Berlin and has established itself as one of the leading European companies in the medical cannabis sector. The company has been listed on the Frankfurt Stock Exchange since 2022 and operates an extensive sourcing network spanning cultivation partners on multiple continents. The partnership with Astrasana marks Cantourage’s entry into the Swiss market and underscores the growing international interest in Switzerland’s regulatory framework for medical cannabis.

Outlook

The collaboration between Cantourage and Astrasana is designed for the long term. Both companies plan to continuously expand their joint product portfolio and respond to the evolving needs of patients and prescribing physicians. Switzerland serves as an important reference market for the further European expansion of both partners.